Cardinal Health (0HTG) Price & Analysis
0HTG Stock Chart & Stats
- Day’s Range
- $250.00 - $260.00
- 52-Week Range
- $179.00 - $264.00
- Previous Close
- $250.25
- Volume
- 1,151
- Average Volume (3M)
- 966
- Market Cap
- $58.00B
- Enterprise Value
- $61.08B
- Total Cash (Recent Filing)
- $4.86B
- Total Debt (Recent Filing)
- $9.95B
- Price to Earnings (P/E)
- 34.5
- Beta
- 0.78
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 2.94
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.82%
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings Growth
Broad-based revenue and operating earnings growth indicates Cardinal Health is converting its distribution scale and healthcare demand into improved financial performance. Continued expansion across pharmaceutical, specialty, and other businesses supports durable earnings momentum beyond a single quarter.
Strong Cash Generation
Robust operating and free cash flow gives Cardinal Health internal funding capacity for investment, debt service, acquisitions, and shareholder returns. The improvement from the prior year also demonstrates stronger cash conversion, although annual results can still vary with working-capital movements.
Contract Visibility And Growth Outlook
Extending the CVS relationship through 2032 preserves an important customer connection and improves visibility into future distribution activity. Reaffirmed FY27 and long-term EPS targets further indicate management expects the contract and broader operating platform to support continued growth.
Bears Say
Negative Equity And Rising Debt
Persistently negative equity and higher debt weaken financial flexibility and make the capital structure more dependent on continued cash generation. This can constrain the company’s ability to absorb operating setbacks, fund expansion, or allocate capital while maintaining a resilient balance sheet.
Structurally Low Margins
Thin distribution margins leave profitability highly sensitive to pricing, product mix, purchasing terms, and cost execution. Even strong revenue growth may translate into limited incremental earnings if expenses or input costs rise, increasing the importance of operational discipline and scale benefits.
Regulatory And Earnings-quality Pressure
Regulatory changes affecting pharmaceutical economics can pressure volume and pricing, while the nonrecurring tariff refund makes recent profit growth less representative of ongoing operations. These factors raise the risk that normalized earnings growth will be below reported results.
0HTG FAQ
What was Cardinal Health’s price range in the past 12 months?
What is Cardinal Health’s market cap?
When is Cardinal Health’s upcoming earnings report date?
How were Cardinal Health’s earnings last quarter?
Is Cardinal Health overvalued?
Does Cardinal Health pay dividends?
What is Cardinal Health’s EPS estimate?
How many shares outstanding does Cardinal Health have?
What happened to Cardinal Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cardinal Health?
What is the TipRanks Smart Score and how is it calculated?
Cardinal Health Stock Smart Score
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Jason Hollar
- Employees
- 61,344
- Website
- www.cardinalhealth.com
- Address
- 7000 Cardinal Place, Dublin, OH, 43017, US
Cardinal Health (0HTG) Earnings & Revenues
0HTG Company Deck
0HTG Earnings Call
Earnings Call SentimentPositive
The call emphasized strong, broad-based fiscal '26 performance across revenue, profit, EPS (Q4 EPS +40% YoY) and cash flow ($5B adjusted FCF), with clear operational momentum in Pharma, Specialty and Other growth businesses and disciplined capital return (share buybacks and increased repurchase authorization). Key risks highlighted include reliance on a nonrecurring $100M IEEPA tariff refund that materially boosted GMPD profitability and $0.31 of Q4 EPS, input cost pressures (fuel and commodity resins), regulatory headwinds (IRA/340B impacts ~500 bps mentioned), and expected near-term cadence softness (Q1 FY27 headwind). Overall, positives around scale, cash generation, segment momentum and reconfirmed long‑term targets materially outweigh the transitory and manageable challenges discussed.
View all GB:0HTG earnings summaries0HTG Net sales Breakdown
- 91.94% Pharmaceutical and Specialty Solutions
- 5.68% Global Medical Products and Distribution
- 2.42% Other
- -0.04% Corporate
0HTG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 6 | 1 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 11 | 0 | 1 |